Lung cancer: diagnosis,staging and treatment |
| |
| Affiliation: | 1. Department of Physics and Materials Science, City University of Hong Kong, Hong Kong;2. Development and Support Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan;3. Department of Biomedical Sciences, City University of Hong Kong, Hong Kong;4. State Key Laboratory in Marine Pollution, City University of Hong Kong, Hong Kong;1. Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan;2. Department of Diagnostic Radiology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan;3. Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan;4. Department of Radiology, Ehime University, Ehime, Japan;1. Departments of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;2. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;3. Division of Hematology-Oncology, Department of Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea |
| |
| Abstract: | ![]()
Lung cancer is common and has a high mortality. Radical (curative intent) surgical resection is recommended for most early-stage non-small cell lung cancers and is also increasingly considered for higher stage tumours. Patients may have co-morbidities that restrict their suitability for surgery. All patients in the UK should be managed via a specialist lung cancer multidisciplinary team, including a thoracic surgeon, to ensure appropriate patient selection for surgery. Chemotherapy and radiotherapy may be used as sole treatment, with surgery, or as part of a palliative management pathway. |
| |
| Keywords: | Curative resection lung cancer operability palliation resectability staging TNM classification |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
